Oxandrolone in Burn Recovery: Evidence, Uses and Risks

Oxandrolone has been studied as an added treatment during specialist recovery from severe burns. Older trials reported gains in selected measures, including body mass and hospital stay.

On this page

Oxandrolone has been studied as an added treatment during specialist recovery from severe burns. Older trials reported gains in selected measures, including body mass and hospital stay. Later adult data were mixed. In the United States, the FDA withdrew Oxandrin approval in 2023. It cited an unfavorable balance of benefits and risks and inadequate evidence of effectiveness.[1]

Evidence boundary: burn research does not support self treatment, a personal amount, routine use after every burn or transfer of pediatric findings to adults. A study history does not create current approval.

Medical, legal and sport sources checked 2 September 2026. This material gives general information. It does not provide a diagnosis, prescription, amount, treatment calendar, product check or drug test timing.

What is oxandrolone?

Oxandrolone is a synthetic anabolic androgenic steroid. Archived United States labeling describes an oral tablet with molecular formula C19H30O3 and molecular mass 306.44 grams per mole. The label also records androgen activity, pituitary gonadotropin suppression and possible effects on sperm production.[3]

Oxandrin and Anavar are brand names associated with oxandrolone. A brand history does not prove that a current product is approved, authentic or suitable for a burn patient. The general identity and nonmedical interest in oxandrolone belong on the Anavar and oxandrolone page. This page stays with severe burn research and care limits.

Oxandrolone identity and authority record
Active substanceOxandrolone
Drug classSynthetic anabolic androgenic steroid
Historical brand namesOxandrin and Anavar
Recorded formulaC19H30O3
Recorded molecular mass306.44 grams per mole
Archived United States routeOral tablet
Current federal controlSchedule III in the United States
Current United States approvalOxandrin approval and four generic applications were withdrawn in 2023

The old tablet label remains useful for chemical identity, warnings and historical wording. It is not proof that the product is currently approved in the United States.

Why can a severe burn cause prolonged muscle loss?

A large burn can trigger a sustained stress response. Resting energy use rises, inflammation persists and the body breaks down protein. Muscle loss can weaken breathing, movement and rehabilitation. Wound closure, graft care, infection control and nutrition place further demands on recovery.[9]

Oxandrolone was studied because androgen receptor activity can support protein synthesis and tissue growth. That mechanism explains the research question. It does not prove that every burn patient gains a net benefit. Age, burn size, organ function, infection, nutrition, surgery, rehabilitation and other medicines can change the result.

Research protocols placed the drug beside specialist burn care. They did not replace fluid care, surgery, wound management, nutrition, infection treatment, pain care or physical rehabilitation. A medicine effect cannot be separated from that background by reading the drug name alone.

What happened to Oxandrin approval in the United States?

Oxandrin was first approved in the United States in 1964. Its older label used broad language about weight gain after severe trauma and other causes of weight loss. That wording was not a current burn protocol and did not settle which burn patients should receive oxandrolone.

The FDA withdrew the Oxandrin application and four generic applications on 28 June 2023. In September 2023, the agency determined that Oxandrin had been withdrawn for reasons of safety or effectiveness. It cited serious liver and lipid warnings and a lack of substantial evidence of effectiveness.[2][1]

United States oxandrolone status timeline
DateAuthority recordMeaning for burn claims
1964Initial Oxandrin approvalHistorical approval began under older evidence and labeling standards.
1984An FDA advisory committee found no evidence of effectivenessThe later FDA determination treated this as part of the evidence problem.
2019The sponsor asked to withdraw the application because the product was no longer marketedCommercial withdrawal alone did not answer the safety or effectiveness question.
28 June 2023The FDA withdrew Oxandrin and four generic application approvalsThe named approvals ended in the United States.
13 September 2023The FDA found withdrawal for reasons of safety or effectivenessThe agency found an unfavorable balance without substantial evidence of effectiveness.
31 October 2025The checked DailyMed record shows a marketing end dateAn archived label can remain visible after marketing and approval status change.

What have oxandrolone burn studies found?

The record includes rehabilitation studies, adult trials, pediatric trials and pooled reviews with different populations, care periods and outcomes.

Selected oxandrolone studies and their limits
RecordPopulation and designReported findingMain limit
2003 rehabilitation studyPeople recovering from severe burns in a rehabilitation settingReported faster regain of body weight and lean mass than nutrition aloneSmall, older study with a narrow recovery setting
2006 adult trialRandomized multicenter trial of 81 adults with burns over 20 to 60 percent of body surface areaReported a shorter hospital stay for the studied groupThe outcome does not prove lower mortality or benefit for smaller burns
2012 pediatric trialSingle center trial in children with burns over 30 percent of body surface area and long follow upReported selected changes in growth, body composition, cardiac work and strengthChildren received specialist care, and results cannot be transferred to adults or smaller burns
2020 systematic reviewReview of 31 burn studiesReported selected gains in weight, lean mass, bone measures and some recovery outcomesStudies varied in design, age, care stage and outcome definition
2024 adult analysisPost hoc study of 1,200 adults from an international trial datasetFound mixed associations and a longer adjusted time to discharge among recipientsClinicians chose oxandrolone, so illness severity and other confounding factors may explain part of the association
2025 pooled reviewFourteen randomized trials with 2,822 patientsReported selected recovery gains but no mortality or infection benefitVery high variation across studies, and the pool included other androgen analogs and combined treatments

The 2024 adult analysis is important because it does not repeat the simple benefit story. Oxandrolone use varied greatly between sites. Recipients often had larger burns or greater illness severity, and the drug itself was not randomly assigned. The authors described the adult findings as mixed and inconclusive.[8]

The 2025 review also needs careful reading. It pooled trials from 2005 through 2025 and reported selected recovery gains. It found no mortality benefit, no clear infection reduction and no donor site healing gain. Adult liver enzyme elevations were more common in the treatment groups. Variation across pooled studies was very high.[9]

What can the evidence support?

Claim level evidence matrix
ClaimEvidence levelSupported readingUnsupported reading
Oxandrolone has been studied after severe burnsEstablishedTrials and reviews include adult and pediatric burn populationsIt is appropriate after every burn
It can affect protein balance and body compositionSupported in selected settingsSome studies reported changes in lean mass, weight or metabolic measuresA predictable result for one patient
It shortens hospital stayConflictingAn older adult trial reported a shorter stayA guaranteed shorter stay under current care
It improves survivalNot shownPooled research has not shown a mortality benefitA life saving effect
It improves wound healingMixedSome older reviews reported selected wound measuresReliable donor site healing across populations
It is safe in severe burn careNot established as a general claimSome trials recorded limited adverse outcomes under specialist careSafety for all ages, organs, medicines or treatment periods
It remains approved in the United StatesFalse for the named applicationsThe FDA withdrew the named approvals in 2023An archived label proves current approval

A group result may have uncertain value for one patient. Burn size, study age, background care, missing data and study design all matter.

Can pediatric findings be applied to adults?

No. Pediatric and adult evidence answers separate questions. Several influential pediatric studies came from one specialist center and enrolled children with very large burns under scheduled care.[6]

Why population transfer is limited
FactorPediatric evidenceAdult evidenceReason for caution
GrowthHeight, bone maturation and puberty can be affectedGrowth plate questions are differentThe same outcome may have a different meaning by age
Burn burdenMany trials required burns over 30 percent of body surface areaAdult studies used other thresholds and case mixesFindings do not represent a small outpatient burn
Background careSpecialist nutrition and rehabilitation were built into protocolsCare practices varied across sitesThe drug cannot be separated from the care system by assumption
Organ and medicine contextPediatric eligibility can exclude many adult conditionsAdults may have heart, liver, kidney or medicine interaction risksBaseline risk changes the balance
Evidence designSome randomized long follow up trials existThe large 2024 adult study was observational for oxandrolone useRandom assignment and treatment selection answer different causal questions

A burn team must assess the injury, current evidence, local approval status and the full clinical record.

What health risks matter with oxandrolone?

The archived label and the 2023 FDA finding describe serious concerns. These include peliosis hepatis, liver failure, internal abdominal bleeding, liver tumors, cholestatic hepatitis and adverse blood lipid changes. The FDA also cited hypercalcemia in some people with breast cancer and prostate concerns in older patients.[1][3]

Health concern and evidence boundary
AreaRecorded concernWhat a normal symptom check cannot rule out
LiverCholestatic hepatitis, jaundice, peliosis, tumors, liver failure or internal bleedingEarly liver injury can occur before severe pain or visible jaundice
Heart and blood vesselsLower high density lipoprotein, higher low density lipoprotein, fluid retention and class wide cardiovascular concernBlood pressure and lipid changes may be silent
Hormones and fertilitySuppressed gonadotropins, reduced natural testosterone and possible sperm suppressionLibido or energy cannot confirm fertility or endocrine recovery
Women and pregnancyVoice change, facial hair, acne, menstrual change and fetal masculinization concernSome virilizing changes may persist after exposure ends
ChildrenAccelerated bone maturation and disturbance of growth or sexual developmentHeight alone cannot show bone age or pubertal effects
Fluid and kidneysEdema can complicate heart, kidney or steroid hormone problemsAnkle swelling or urine change needs context and may have several causes
Mental health and dependenceBroader anabolic steroid evidence includes mood change, dependence and withdrawal symptomsA calm appearance does not rule out depression or dangerous thoughts

Direct oxandrolone rates are unknown for many events. Burn illness can also alter liver tests, fluid balance, mood and blood values. Clinical interpretation must separate possible causes.[14][15]

Which interactions and higher risk settings need attention?

The archived label records a strong interaction with oral anticoagulants, including warfarin. Oxandrolone can increase anticoagulant sensitivity and bleeding risk. A patient using warfarin needs the prescribing team to know about every oxandrolone exposure. Medicine changes should not be made from an online summary.[3]

The label also records possible interactions with oral diabetes medicines. Corticosteroids or adrenocorticotropic hormone can add to edema. Pregnancy, nephrosis, hypercalcemia and certain breast or prostate cancers appear in the archived contraindication record.[3]

Burn care often involves pain medicines, antibiotics, anticoagulants, nutrition products and several clinical teams. A complete medicine list points because one interaction can affect bleeding, glucose, fluid balance, liver tests or rehabilitation. Product labels and photographs may help record a claim, but they do not confirm contents.

What may a specialist burn team assess?

A burn team first considers the injury, not one medicine. Relevant details include burn depth, total body surface area, airway injury, operations, grafts, infection, nutrition, mobility, pain, organ function and rehabilitation progress.

Medicine review may cover prescriptions, supplements, hormones, anticoagulants, diabetes medicines and unregulated products. Depending on the clinical question, assessment may include blood pressure, examination, blood count, liver and kidney measures, lipids, glucose, pregnancy status or hormone tests. No single panel answers every safety question.

Bring discharge records, medicine lists and product photographs. Report exposure dates and symptom changes. Honest disclosure can prevent a missed interaction or incorrect explanation.

Read how to talk with a doctor about anabolic steroid use and what blood tests can and cannot show.

What is the legal and sport status of oxandrolone?

Medicine approval, controlled drug law and sport rules answer different questions. The table gives current examples checked on 2 September 2026. Individual cases can depend on conduct, location, prescription facts and later rule changes.

Current legal and sport records
SystemRecordLimit
United States federal lawOxandrolone is listed as a Schedule III anabolic steroid.[10]Federal scheduling does not describe every state rule or individual case.
United KingdomOxandrolone appears as Class C and Schedule 4 Part 2.[11]Possession, supply and import treatment differ under the applicable rules.
CanadaOxandrolone appears in Schedule IV of the Controlled Drugs and Substances Act.[12]The legal result depends on the conduct and any applicable authorization.
Competitive sportThe 2026 World Anti Doping Agency list prohibits oxandrolone under category S1 at all times.[13]A research history or prior prescription does not by itself create a therapeutic use exemption.

This is general information, not legal advice. The page does not provide a detection window, masking method or rule avoidance advice.

Can a label prove that a product contains oxandrolone?

No. A printed name, tablet color, seller statement or online photograph cannot prove identity, amount, purity or contamination status. An archived medicine label describes the named regulated product at a point in time. It does not authenticate material from another source.

A product sold as Anavar or oxandrolone may contain another active drug, an undeclared mixture or no oxandrolone. A chemical test answers only the method and sample examined. It cannot show that another tablet or batch is the same.

After a suspected exposure, retain packaging and write down the source claim, dates, symptoms and other medicines. Share the record with a clinician or poison service. Severe symptoms need emergency care rather than a product search.

References

  1. FDA determination that Oxandrin was withdrawn for reasons of safety or effectiveness. 2023.
  2. FDA withdrawal of Oxandrin and four oxandrolone applications. 2023.
  3. Archived United States oxandrolone tablet label. 2022.
  4. Oxandrolone and lean mass during rehabilitation after severe burns. 2003.
  5. Multicenter randomized trial in adults with severe burns. 2006.
  6. Five year pediatric oxandrolone trial after severe burns. 2012.
  7. Systematic review of oxandrolone in burn injuries. 2020.
  8. Adult burn analysis from the RE ENERGIZE trial dataset. 2024.
  9. Updated review of androgen analog trials in burn patients. 2025.
  10. Current United States Schedule III rule. 2026.
  11. United Kingdom controlled drugs list. 2025.
  12. Canada Controlled Drugs and Substances Act, Schedule IV. 2026.
  13. World Anti Doping Agency 2026 Prohibited List. 2026.
  14. Endocrine Society statement on health effects of performance drugs. 2014.
  15. Clinical review of anabolic androgenic steroid assessment. 2019.